ArticleRheumatology international2019
Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study.
Article in Rheumatology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Elevated level of circulating calprotectin correlates with severity and high mortality in patients with COVID-19.Immunity, inflammation and disease · 2024Pooled it
- Article
- Association of Elevated Serum S100A8/A9 Levels and Cognitive Impairment in Patients With Systemic Lupus Erythematosus.Arthritis care & research · 2025Article
- Mechanism of action and therapeutic potential of S100A8/A9 in neuroinflammation and cognitive impairment: From molecular target to clinical application (Review).International journal of molecular medicine · 2025Review
- Changes of Peripheral T Cells in Systemic Lupus Erythematosus Patients.Immunity, inflammation and disease · 2025Article
- Comparing the Effect of Heat Therapy and Mitochondrial-Targeted Antioxidants in Polycystic Ovarian Syndrome Phenotype Induced by Junk Food Consumption.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- A pilot study of S100A4, S100A8/A9, and S100A12 in dilated cardiomyopathy: novel biomarkers for diagnosis or prognosis?ESC heart failure · 2024Article
- Proteomic analysis identifies subgroups of patients with active systemic lupus erythematosus.Clinical proteomics · 2023Article
- Serum Calprotectin - a NET Product - as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Serum S100A8/A9 concentrations are associated with neuropsychiatric involvement in systemic lupus erythematosus: a cross-sectional study.BMC rheumatology · 2022Article
- Neutralization of S100A4 induces stabilization of atherosclerotic plaques: role of smooth muscle cells.Cardiovascular research · 2022Article
- Vitronectin, a Novel Urinary Proteomic Biomarker, Promotes Cell Pyroptosis in Juvenile Systemic Lupus Erythematosus.Mediators of inflammation · 2022Article
- S100A8 in Serum, Urine, and Saliva as a Potential Biomarker for Systemic Lupus Erythematosus.Frontiers in immunology · 2022Article
- Exosomes as Crucial Players in Pathogenesis of Systemic Lupus Erythematosus.Journal of immunology research · 2022Review
- Genetic in situ engineering of myeloid regulatory cells controls inflammation in autoimmunity.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Evaluation of S100A12 protein levels in children with familial Mediterranean feverTurkish journal of medical sciences · 2021Article
- Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis.Journal of neuroinflammation · 2021Article
- Circulating Calprotectin as a Biomarker of COVID-19 Severity.Expert review of clinical immunology · 2021Review
- Emerging Molecular Markers Towards Potential Diagnostic Panels for Lupus.Frontiers in immunology · 2021Review
- Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants-A Potential Novel Biomarker of Disease Activity.Frontiers in neurology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
Abstract
S100 proteins are currently being investigated as potential diagnostic and prognostic biomarkers of several cancers and inflammatory diseases. The aims of this study were to analyse the plasma levels of S100A4, S100A8/9 and S100A12 in patients with incomplete systemic lupus erythematosus (iSLE), in patients with established SLE and in healthy controls (HCs) and to investigate the potential utility of the S100 proteins as diagnostic or activity-specific biomarkers in SLE. Plasma levels were measured by ELISA in a cross-sectional cohort study of 44 patients with SLE, 8 patients with iSLE and 43 HCs. Disease activity was assessed using the SLEDAI-2K. The mean levels of all S100 proteins were significantly higher in SLE patients compared to HCs. In iSLE patients, the levels of S100A4 and S100A12 but not S100A8/9 were also significantly higher compared to HCs. There were no significant differences in S100 levels between the iSLE and SLE patients. Plasma S100 proteins levels effectively discriminated between SLE patients and HCs. The area under the curve (AUC) for S100A4, S100A8/9 and S100A12 plasma levels was 0.989 (95% CI 0.976-1.000), 0.678 (95% CI 0.563-0.792) and 0.807 (95% CI 0.715-0.899), respectively. S100 levels did not differentiate between patients with high and low disease activity. Only the S100A12 levels were significantly associated with SLEDAI-2K and with cSLEDAI-2K. S100 proteins were significantly higher in SLE patients compared HCs and particularly S100A4 could be proposed as a potential diagnostic biomarker for SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.